Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides

Journal of Medicinal Chemistry

Volumn 55, Issue 21, 2012, Pages 9346-9361

  Berg, Stefan ^a   Swahn, Britt Marie ^a   Kolmodin, Karin ^a   Karlström, Sofia ^a   Von Berg, Stefan ^a   Söderman, Peter ^a   Holenz, Jörg ^a   Lindström, Johan ^a   Sundström, Marie ^a   Turek, Dominika ^a   Kihlström, Jacob ^a   Slivo, Can ^a   Andersson, Lars ^a   Pyring, David ^a   Rotticci, Didier ^a   Öhberg, Liselotte ^a   Kers, Annika ^a   Bogar, Krisztian ^a   Von Kieseritzky, Fredrik ^a   Bergh, Margareta ^a   Olsson, Lise Lotte ^b   Janson, Juliette ^a   Eketjäll, Susanna ^a   Georgievska, Biljana ^a   Jeppsson, Fredrik ^a   Fälting, Johanna ^a   more..

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE INHIBITOR; AZD 3839; BETA SECRETASE 1; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; MOUSE; NONHUMAN;

ADMINISTRATION, ORAL; ALKYNES; AMIDES; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HYDROGEN BONDING; INDOLES; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PERMEABILITY; PYRIMIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84868562686     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3009025     Document Type: Article

References (59)

1. Alzheimers Association. Alzheimers disease facts and figures. Alzheimers Dementia 2010, 6, 158, 194.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics Science 2002, 297, 353-356
3. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein β-secretase from human brain Nature 1999, 402, 537-540
4. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. β-secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999, 286, 735-741
5. Vassar, R.; Kovacs, D. M.; Yan, R.; Wong, P. C. The β-secretase enzyme in health and Alzheimers disease: regulation, cell biology, function, and therapeutic potential J. Neurosci. 2009, 29, 12787-12794
6. Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B. D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; Martin, L.; Louis, J.-C.; Yan, Q.; Richards, W. G.; Citron, M.; Vassar, R. Mice deficient in BACE1, the Alzheimers β-secretase, have normal phenotype and abolished β-amyloid generation Nat. Neurosci. 2001, 4, 231-232
7. Roberds, S. L.; Anderson, J.; Basi, G.; Bienkowski, M. J.; Branstetter, D. G.; Chen, K. S.; Freedman, S. B.; Frigon, N. L.; Games, D.; Hu, K.; Johnson-Wood, K.; Kappenman, K. E.; Kawabe, T. T.; Kola, I.; Kuehn, R.; Lee, M.; Liu, W.; Motter, R.; Nichols, N. F.; Power, M.; Robertson, D. W.; Schenk, D.; Schoor, M.; Shopp, G. M.; Shuck, M. E.; Sinha, S.; Svensson, K. A.; Tatsuno, G.; Tintrup, H.; Wijsman, J.; Wright, S.; McConlogue, L. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimers disease therapeutics Hum. Mol. Genet. 2001, 10, 1317-1324
8. Citron, M. Alzheimers disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387-398
9. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimers disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discovery 2011, 10, 698-712
10. Rueeger, H.; Lueoend, R.; Rogel, O.; Rondeau, J.-M.; Mobitz, H.; Machauer, R.; Jacobson, L.; Staufenbiel, M.; Desrayaud, S.; Neumann, U. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides J. Med. Chem. 2012, 55, 3364-3386
11. Weiss, M. M.; Williamson, T.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dineen, T. A.; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; Rattan, C.; San Miguel, T.; Sickmier, E. A.; Wahl, R. C.; Wen, P. H.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. J. Med. Chem. 2012, in press.
12. Cole, D. C.; Manas, E.; S.; Stock, J. R.; Condon, J. S.; Jennings, L. D.; Aulabaugh, A.; Chopra, R.; Cowling, R.; Ellingboe, J. W.; Fan, K. Y.; Harrison, B. L.; Hu, Y.; Jacobsen, S.; Jin, G.; Lin, L.; Lovering, F. E.; Malamas, M. S.; Stahl, J.; Strand, J.; Sukhedo, M. N.; Svenson, K.; Turner, M. J.; Wagner, E.; Wu, J.; Zhou, P.; Bard, J. Acylguanidines as small-molecule β-secretase inhibitors J. Med. Chem. 2006, 49, 6158-6161
13. Malamas, M. S.; Erdei, J.; Gunawan, I.; Barnes, K.; Johnson, M.; Hui, Y.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Olland, A.; Bard, J.; Robichaud, A. J. Aminoimidazoles as potent and selective human β-secretase (BACE1) inhibitors J. Med. Chem. 2009, 52, 6314-6323
14. Baxter, E. W.; Conway, K. A.; Kennis, L.; Bischoff, F.; Mercken, M. H.; Winter, H. L.; Reynolds, C. H.; Tounge, B. A.; Luo, C.; Scott, M. K.; Huang, Y.; Braeken, M.; Pieters, S. M.; Berthelot, D. J.; Masure, S.; Bruinzeel, W. D.; Jordan, A. D.; Parker, M. H.; Boyd, R. E.; Qu, J.; Alexander, R. S.; Brenneman, D. E.; Reitz, A. B. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead J. Med. Chem. 2007, 50, 4261-4264
15. Zhu, Z.; Sun, Z.-Y.; Ye, Y.; Voigt, J.; Strickland, C.; Smith, E. M.; Cumming, J.; Wang, L.; Wong, J.; Wang, Y.-S.; Wyss, D. F.; Chen, X.; Kuvelkar, R.; Kennedy, M. E.; Favreau, L.; Parker, E.; McKittrick, B. A.; Stamford, A.; Czarniecki, M.; Greenlee, W.; Hunter, J. C. Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: part I-inhibitor design and validation J. Med. Chem. 2010, 53, 951-965
16. Berg, S.; Burrows, J.; Chessari, G.; Congreve, M. S.; Hedström, J.; Hellberg, S.; Högdin, K.; Kihlström, J.; Kolmodin, K.; Lindström, J.; Murray, C.; Patel, S. Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimers disease, neurodegeneration and dementia. Patent WO2007058602, 2007.
17. Congreve, M.; Aharony, D.; Albert, J.; Callaghan, O.; Campbell, J.; Carr, R. A. E.; Chessari, G.; Cowan, S.; Edwards, P. D.; Frederickson, M.; McMenamin, R.; Murray, C. W.; Patel, S.; Wallis, N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase J. Med. Chem. 2007, 50, 1124-1132
18. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L.-L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50, 5912-5925
19. Cheng, Y.; Judd, T. C.; Bartberger, M. D.; Brown, J.; Chen, K.; Fremeau, R. T.; Hickman, D.; Hitchcock, S. A.; Jordan, B.; Li, V.; Lopez, P.; Louie, S. W.; Luo, Y.; Michelsen, K.; Nixey, T.; Powers, T. S.; Rattan, C.; Sickmier, E. A., St; Jean, D. J., Jr.; Wahl, R. C.; Wen, P. H.; Wood, S. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) J. Med. Chem. 2011, 54, 5836-5857
20. Stanton, M. G.; Stauffer, S. R.; Gregro, A. R.; Steinbeiser, M.; Nantermet, P.; Sankaranarayanan, S.; Price, E. A.; Wu, G.; Crouthamel, M.-C.; Ellis, J.; Lai, M.-T.; Espeseth, A. S.; Shi, X.-P.; Jin, L.; Colussi, D.; Pietrak, B.; Huang, Q.; Xu, M.; Simon, A. J.; Graham, S. L.; Vacca, J. P.; Selnick, H. Discovery of isonicotinamide derived β-secretase inhibitors: in vivo reduction of β-amyloid J. Med. Chem. 2007, 50, 3431-3433
21. Sankaranarayanan, S; Holahan, M. A.; Colussi, D.; Crouthamel, M.-C.; Devanarayan, V.; Ellis, J.; Espeseth, A.; Gates, A. T.; Graham, S. L.; Gregro, A. R.; Hazuda, D.; Hochman, J. H.; Holloway, K.; Jin, L.; Kahana, J.; Lai, M.-T.; Lineberger, J.; McGaughey, G.; Moore, K. P.; Nantermet, P.; Pietrak, B.; Price, E. A.; Rajapakse, H.; Stauffer, S.; Steinbeiser, M. A.; Seabrook, G.; Selnick, H. G.; Shi, X.-P.; Stanton, M. G.; Swestock, J.; Tugusheva, K.; Tyler, K. X.; Vacca, J. P.; Wong, J.; Wu, G.; Xu, M.; Cook, J. J.; Simon, A. J. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates J. Pharmacol. Exp. Ther. 2009, 328, 131-140
22. Zhu, H.; Young, M. B.; Nantermet, P. G.; Graham, S. L.; Colussi, D.; Lai, M.-T.; Pietrak, B.; Price, E. A.; Sankaranarayanan, S.; Shi, X. P.; Tugusheva, K.; Holahan, M. A.; Michener, M. S.; Cook, J. J.; Simon, A.; Hazuda, D. J.; Vacca, J. P.; Rajapakse, H. A. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1779-1782
23. Cumming, J. N.; Smith, E. M.; Wang, L.; Misiaszek, J.; Durkin, J.; Pan, J.; Iserloh, U.; Wu, Y.; Zhu, Z.; Strickland, C.; Voigt, J.; Chen, X.; Kennedy, M. E.; Kuvelkar, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Czarniecki, M. F.; Greenlee, W. J.; McKittrick, B. A.; Parker, E. M.; Stamford, A. W. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 2444-2449
24. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; Smith Labell, E.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Hall, G. D.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
25. Swahn, B.-M.; Holenz, J.; Kihlström, J.; Kolmodin, K.; Lindström, J.; Plobeck, N.; Rotticci, D.; Sehgelmeble, F.; Sundström, M.; von Berg, S.; Fälting, J.; Georgievska, B.; Gustavsson, S.; Neelissen, J.; Ek, M.; Olsson, L.-L.; Berg, S. Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy Bioorg. Med. Chem. Lett. 2012, 22, 1854-1859
26. Roden, D. M. Drug-induced prolongation of the QT interval N. Engl. J. Med. 2004, 350, 1013-1022
27. Vik, T.; Pollard, C.; Sager, P. Early clinical development: evaluation of drug-induced torsades de pointes risk Pharmacol Ther. 2008, 119, 210-214
28. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
29. Malamas, M. S.; Erdei, J.; Gunawan, I.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Chopra, R.; Olland, A.; Bard, J.; Jacobsen, S.; Magolda, R. L.; Pangalos, M.; Robichaud, A. J. Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors J. Med. Chem. 2010, 53, 1146-1158
30. Hong, L.; Koelsch, G.; Lin, X. L.; Wu, S. L.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor Science 2000, 290, 150-153
31. Cumming, J. G.; Tucker, H.; Oldfield, J.; Fielding, C.; Highton, A.; Faull, A.; Wild, M.; Brown, D.; Wells, S.; Shaw, J. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis Bioorg. Med. Chem. Lett. 2012, 22, 1655-1659
32. Leeson, P. D.; Empfield, J. R. Reducing the risk of drug attrition associated with physicochemical properties Annu. Rep. Med. Chem. 2010, 45, 393-407
33. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
34. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Webb, E. F.; Hall, R.; Sorenson, M.; Lee, J. C.; Ayrton, A.; Griswold, D. E.; Gallagher, T. F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116
35. Stachel, S. J.; Coburn, C. A.; Rush, D.; Jones, K. L. G.; Zhu, H.; Rajapakse, H.; Graham, S. L.; Simon, A.; Holloway, M. K.; Allison, T. J.; Munshi, S. K.; Espeseth, A. S.; Zuck, P.; Colussi, D.; Wolfe, A.; Pietrak, B. L.; Lai, M.-T.; Vacca, J. P. Discovery of aminoheterocycles as a novel β-secretase inhibitor class: pH dependence on binding activity part 1 Bioorg. Med. Chem. Lett. 2009, 19, 2977-2980
36. Dominguez, J. L.; Christopeit, T.; Villaverde, M. C.; Gossas, T.; Otero, J. M.; Nystrom, S.; Baraznenok, V.; Lindstrom, E.; Danielson, U. H.; Sussman, F. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1 Biochemistry 2010, 49, 7255-7263
37. Bridgland-Taylor, M. H.; Hargreaves, A. C.; Easter, A.; Orme, A.; Henthorn, D. C.; Ding, M.; Davis, A. M.; Small, B. G.; Heapy, C. G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T. G.; Sullivan, E.; Valentin, J. P.; Pollard, C. E. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT J. Pharmacol. Toxicol. Methods 2006, 54, 189-199
38. Schroeder, K.; Neagle, B.; Trezise, D. J.; Worley, J. IonWorks: a new high-throughput electrophysiology measurement platform J. Biomol. Screening 2003, 8, 50-64
39. Floby, E.; Briem, S.; Terelius, Y.; Sohlenius-Sternbeck, A.-K. The use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations Xenobiotica 2004, 34, 949-959
40. Bissell, D. M.; Guzelian, P. S. Phenotypic stability of adult rat hepatocytes in primary monolayer culture Ann. N. Y. Acad. Sci. 1980, 249, 85-98
41. Wan, H; Holmén, A; Wang, Y. D.; Lindberg, W; Englund, M; Någård, M; Thompson, R. High throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry Rapid Commun. Mass Spectrom. 2003, 1, 2639-2648
42. Wan, H; Holmén, A; Någård, M; Lindberg, W. Rapid screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis combined with short-end injection J. Chromatogr., A 2002, 979, 369-377
43. oct: a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds J. Med. Chem. 2001, 44, 2490-2497
44. Laurence, C.; Brameld, K. A.; Graton, J.; Le Questel, J.-Y.; Renault, E. The pKBHX Database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 2009, 52, 4073-4086
45. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemists guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
46. Zhou, P.; Li, Y.; Fan, Y.; Wang, Z.; Chopra, R.; Olland, A.; Hu, Y.; Magolda, R. L.; Pangalos, M.; Reinhart, P. H.; Turner, M. J.; Bard, J.; Malamas, M. S.; Robichaud, A. J. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 2326-2329
47. Malamas, M. S.; Robichaud, A.; Erdei, J.; Quagliato, D.; Solvibile, W.; Zhou, P.; Morris, K.; Turner, J.; Wagner, E.; Fan, K.; Olland, A.; Jacobsen, S.; Reinhart, P.; Riddell, D.; Pangalos, M. Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability Bioorg. Med. Chem. Lett. 2010, 20, 6597-6605
48. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and inhibitor complex structures of BACE (β-secretase) J. Mol. Biol. 2004, 343, 407-416
49. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291
50. Borgegård, T.; Minidis, A.; Juréus, A.; Malmborg, J.; Rosqvist, S.; Gruber, S.; Almqvist, H.; Yan, H.; Bogstedt, A.; Olsson, F.; Dahlström, J.; Ray, C.; Närhi, K.; Malinowsky, D.; Hagström, E.; Jin, S.; Malmberg, A.; Lendahl, U.; Lundkvist, J. In vivo analysis using a presenilin-1-specific inhibitor. Presenilin-1-containing gamma;-secretase complexes mediate the majority of CNS Aβ production in the mouse Alzheimer Dis. Res. J. 2011, 3, 29-45
51. Friden, M.; Gupta, A.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids Drug Metab. Dispos. 2007, 35, 1711
52. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsl. Protein Crystallogr. 1992, No. 26.
53. Collaborative Computational Project, number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, D50, 760-763.
54. Vonrhein, C.; Flensburg, C.; Keller, P.; Sharff, A.; Smart, O. S.; Paciorek, W.; Womack, T. O.; Bricogne, G. Data processing and analysis with the autoPROC toolbox Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, D67, 293-302
55. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, D66, 125-132
56. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, D53, 240-255
57. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version 2.11.1; Global Phasing Ltd.: Cambridge, U.K., 2011.
58. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, D60, 2126-2132
59. Delano, W. L. The PyMOL Molecular Graphis System; Delano Scientific: Palo Alto, CA, 2002.